The short interest data are out for the September 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest jump to 10.4 million shares from the previous level of 9.24 million. Shares closed Thursday at $143.51, in a 52-week trading range of $127.67 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest rise to 4.59 million shares from the previous 3.86 million. Shares closed Thursday at $293.01, within a 52-week trading range of $265.00 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 14.95 million shares from the previous reading of 12.50 million. The mid-May level was the highest short interest reading year to date. Shares of Celgene closed Thursday at $113.88, in a 52-week range of $83.16 to $140.72.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest rise to 29.60 million shares, from 25.65 million in the previous period. The late July reading was the lowest of the year. Shares closed Thursday at $102.51, in a 52-week trading range of $85.95 to $123.37.
ALSO READ: The 6 Most Shorted Nasdaq Stocks
MannKind Corp. (NASDAQ: MNKD) saw its short interest decrease very slightly to 126.66 million shares. The previous reading was 126.70 million. This is the second highest reading on the year. Shares closed Thursday at $3.46, in a 52-week trading range of $3.20 to $7.88.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 6.66 million from the previous level of 5.39 million. The mid-June level was far and away the highest reading on the year, and since that time shares have backed off significantly. Shares closed Thursday at $157.05, in a 52-week range of $150.06 to $208.88.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
